SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Neurobiological Tech (NTII)
NTII 0.00010000.0%Mar 7 3:00 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: maileg who wrote (45)12/18/1996 6:55:00 PM
From: John Metcalf   of 1494
 
Significant milestone, you betcha, but new thread....

Thanks, John de C for keeping us updated on Memantine, the most exciting of NTII's prospects. Dynorphin-A was shown to reduce morphine use in published data this Fall, and there were also positive results on CRF in brain edema.

Do you have updates on these products? Also, how many clinicals can NTII afford to run simultaneously? Three drugs in the clinic seems like a lot for such a small company. AACTG must be picking up some Memantine trial cost, but still, they have to be assessing their ability to fund all this.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News